Abstract:Tetanus neurotoxin causes the disease tetanus, which is characterized by rigid paralysis. The toxin acts by inhibiting the release of neurotransmitters from inhibitory neurons in the spinal cord that innervate motor neurons and is unique among the clostridial neurotoxins due to its ability to shuttle from the periphery to the central nervous system. Tetanus neurotoxin is thought to interact with a high affinity receptor complex that is composed of lipid and protein components; however, the identity of the protein receptor remains elusive. In the current study, we demonstrate that toxin binding, to dissociated hippocampal and spinal cord neurons, is greatly enhanced by driving synaptic vesicle exocytosis. Moreover, tetanus neurotoxin entry and subsequent cleavage of synaptobrevin II, the substrate for this toxin, was also dependent on synaptic vesicle recycling. Next, we identified the potential synaptic vesicle binding protein for the toxin and found that it corresponded to SV2; tetanus neurotoxin was unable to cleave synaptobrevin II in SV2 knockout neurons. Toxin entry into knockout neurons was rescued by infecting with viruses that express SV2A or SV2B. Tetanus toxin elicited the hyper excitability in dissociated spinal cord neurons - due to preferential loss of inhibitory transmission - that is characteristic of the disease. Surprisingly, in dissociated cortical cultures, low concentrations of the toxin preferentially acted on excitatory neurons. Further examination of the distribution of SV2A and SV2B in both spinal cord and cortical neurons revealed that SV2B is to a large extent localized to excitatory terminals, while SV2A is localized to inhibitory terminals. Therefore, the distinct effects of tetanus toxin on cortical and spinal cord neurons are not due to differential expression of SV2 isoforms. In summary, the findings reported here indicate that SV2A and SV2B mediate binding and entry of tetanus neurotoxin into central neurons.

Cytotoxicity of botulinum neurotoxins reveals a direct role of syntaxin 1 and SNAP-25 in neuron survival

None Detectable Retrograde Transport Of Chinese Botulinum Toxin Type A In Mice By Single Intramuscular Injection

Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release

Syntaxin 1a Promotes the Endocytic Sorting of Eaac1 Leading to Inhibition of Glutamate Transport

Antinociceptive Effect of Botulinum Toxin A Involves Alterations in AMPA Receptor Expression and Glutamate Release in Spinal Dorsal Horn Neurons

Unilateral Whisker Pad Injection of Botulinum Toxin Type a Enhances Spatial Learning in Mice.

Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly.

SNAP-25 Functional Domains in SNARE Core Complex Assembly and Glutamate Release of Cerebellar Granule Cells

Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2

Intramuscular Botulinum Neurotoxin Serotypes E and A Elicit Distinct Effects on SNAP25 Protein Fragments, Muscular Histology, Spread and Neuronal Transport: An Integrated Histology-Based Study in the Rat

The Kv2.1 Channels Mediate Neuronal Apoptosis Induced by Excitotoxicity

Induction of Autophagy in Neurite Degeneration of Mouse Superior Cervical Ganglion Neurons

Cytosolic prion protein induces apoptosis in human neuronal cell SH-SY5Y via mitochondrial disruption pathway.

SV2 Mediates Entry of Tetanus Neurotoxin into Central Neurons

Potentiated necrosis of cultured cortical neurons by neurotrophins

Syntaxin 1a Co-Associates with Native Rat Brain and Cloned Large Conductance, Calcium-Activated Potassium Channels in Situ

Botulinum toxin intoxication requires retrograde transport and membrane translocation at the ER in RenVM neurons

Microarray analysis of differentially regulated genes in human neuronal and epithelial cell lines upon exposure to type A botulinum neurotoxin

APP β-CTF triggers cell-autonomous synaptic toxicity independent of Aβ

Recombinant luminal domain of human synaptotagmin II in combination with gangliosides inhibits the toxicity of botulinum neurotoxins in mice.